LifeCell cut to hold by Wells Fargo

LifeCell Corp. was downgraded Friday by Wells Fargo Securities to hold from buy. The Branchburg N.J.-based biotech develops products made of human tissue for use in reconstructive, urogynecologic and orthopedic surgical procedures. LifeCell shares slipped Friday by 7 cents, or 0.48%, to close at $14.60 on volume of 673,894 shares versus the three-month running average of 447,108.

Vicuron cut to hold by Legg Mason

Vicuron Pharmaceuticals Inc. was downgraded Friday by Legg Mason to hold from buy. The King of Prussia, Pa.-based biotech, focused on antibiotics, is being acquired by Pfizer Inc. for $1.9 billion. Vicuron shares dipped Friday by 22 cents, or 0.78%, to close at $27.99 on volume of 6 million shares versus the three-month running average of 793,968.

Abgenix rated outperform by Wachovia

Abgenix Inc. coverage was initiated Friday by Wachovia Securities at outperform. The Fremont, Calif.-based biotech develops human therapeutic antibodies for the treatment of various disease conditions, including cancer, inflammation, and metabolic disease. Abgenix shares gained Friday by 62 cents, or 7.46%, to close at $8.93 on volume of 4.33 million shares versus the three-month running average of 1.53 million.

Abgenix initiated at strong buy by First Albany

Hythiam Inc. coverage was initiated Friday by First Albany with a "strong buy" rating. The Los Angeles-based company is engaged research and commercialization of physiological treatment protocols for the treatment of alcoholism and other substance dependencies in the United States. Hytiam shares gained Friday by 10.36 cents, or 1.91%, to close at $5.5236 on volume of 768,789 shares versus the three-month running average of 129,327.

Ivax rated buy by Smith Barney

Ivax Corp. coverage was initiated Friday by Smith Barney Citigroup with a buy rating. The Miami-based generic drug company is primarily focused on respiratory treatments. Ivax shares rose Friday by 43 cents, or 2.09%, to close at $21.00 on volume of 3.96 million shares versus the three-month running average of 2.39 million.

Vion started at buy by Wedbush Morgan

Vion Pharmaceuticals Inc. coverage was initiated Friday by Wedbush Morgan with a buy rating. The New Haven, Conn.-based biotech is focused cancer treatments. Vion shares were up Friday by 9 cents, or 3.93%, to close at $2.38 on volume of 1.11 million shares versus the three-month running average of 717,971.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.